SFS
EIDX

Sowell Financial Services’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Sowell Financial Services’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-120
Closed -$6K – 2802
2020
Q2 		$6K Sell
120
-570
-83% -$26.5K ﹤0.01% 1873
2020
Q1 		$34K Sell
690
-300
-30% -$15.3K ﹤0.01% 1191
2019
Q4 		$57K Buy
990
+950
+2,375% +$47K ﹤0.01% 1117
2019
Q3 		$1K Buy
+40
New +$1.56K ﹤0.01% 2358

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Sowell Financial Services's EIDX Position: Q3 2020 in Review

Sowell Financial Services sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q3 2020, closing a stake of 120 shares — an estimated $6K sold.

Sowell Financial Services first reported a position in EIDX in Q3 2019 and held it in 4 quarters. The position peaked at $57K in Q4 2019. 91 funds tracked by Wall St. Rank hold EIDX as of Q3 2020.

  • Sowell Financial Services reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Sowell Financial Services sold 120 Eidos Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $6K.
  • Sowell Financial Services first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2019 and held it in 4 quarters.
  • Sowell Financial Services's Eidos Therapeutics, Inc. Common Stock position peaked at $57K in Q4 2019.
  • 91 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Sowell Financial Services's 13F filing for Q3 2020, filed 12 Nov 2020.